Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tarloxotinib - Rain Oncology/University of Auckland

Next Previous
Drug Profile

Tarloxotinib - Rain Oncology/University of Auckland

Alternative Names: Hypoxin™; PR 610; Tarlox; Tarloxotinib bromide; TH-4000

Latest Information Update: 11 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Auckland
  • Developer Proacta; Rain Oncology; Threshold Pharmaceuticals
  • Class Aniline compounds; Antineoplastics; Imidazoles; Pyridines; Pyridones
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Discontinued Solid tumours; Squamous cell cancer

Most Recent Events

  • 31 Dec 2023 Rain Oncology terminates a phase I/II clinical trials in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (IV) due to business reasons (NCT05313009)
  • 14 Mar 2022 University of Auckland plans a phase I trial for Head and neck cancer (Late-stage disease, First-line therapy) in Australia and New Zealand (ACTRN12622000369729)
  • 07 Mar 2022 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT05313009)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top